Characteristics and Risk Factors of Post-Infection Irritable Bowel Syndrome After Campylobacter Enteritis.
Epidemiology
Foodborne Illness
Functional GI Disorders
Gastroenteritis
Microbiome
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
22
04
2020
revised:
25
06
2020
accepted:
16
07
2020
pubmed:
28
7
2020
medline:
10
9
2021
entrez:
26
7
2020
Statut:
ppublish
Résumé
Campylobacter is the leading cause of bacterial gastroenteritis in the United States. We investigated the prevalence of postinfection irritable bowel syndrome (PI-IBS) in a cohort with culture-confirmed Campylobacter cases; risk factors for PI-IBS based on clinical factors; and shifts in IBS patterns postinfection in patients with pre-existing IBS. The Minnesota Department of Health collects data on symptoms and exposures upon notification of Campylobacter cases. From 2011 through 2019, we sent surveys (the Rome III and IBS symptom severity surveys) to 3586 patients 6 to 9 months after Campylobacter infection. The prevalence of PI-IBS was estimated and risk factors were assessed using multivariable logistic regression. There were 1667 responders to the survey, 249 of whom had pre-existing IBS. Of the 1418 responders without pre-existing IBS, 301 (21%) subsequently developed IBS. Most of these individuals had IBS-mixed (54%), followed by IBS-diarrhea (38%), and IBS-constipation (6%). The mean IBS symptom severity score was 218 (indicating moderate severity). Female sex, younger age, bloody stools, abdominal cramps, and hospitalization during acute enteritis were associated with increased risk, whereas fever was protective for the development of PI-IBS. Antibiotic use and exposure patterns were similar between PI-IBS and control groups. Among patients with IBS-mixed or IBS-diarrhea before infection, 78% retained their subtypes after infection. In contrast, only 50% of patients with IBS-constipation retained that subtype after infection, whereas 40% transitioned to IBS-mixed. Of patients with pre-existing IBS, 38% had increased frequency of abdominal pain after Campylobacter infection. In a cohort of patients with Campylobacter infection in Minnesota, 21% developed PI-IBS; most cases reported mixed IBS or diarrhea of moderate severity. Demographic and clinical factors during acute enterocolitis are associated with PI-IBS development. Campylobacter infection also can result in a switch of a pre-existing IBS phenotype.
Sections du résumé
BACKGROUND & AIMS
Campylobacter is the leading cause of bacterial gastroenteritis in the United States. We investigated the prevalence of postinfection irritable bowel syndrome (PI-IBS) in a cohort with culture-confirmed Campylobacter cases; risk factors for PI-IBS based on clinical factors; and shifts in IBS patterns postinfection in patients with pre-existing IBS.
METHODS
The Minnesota Department of Health collects data on symptoms and exposures upon notification of Campylobacter cases. From 2011 through 2019, we sent surveys (the Rome III and IBS symptom severity surveys) to 3586 patients 6 to 9 months after Campylobacter infection. The prevalence of PI-IBS was estimated and risk factors were assessed using multivariable logistic regression.
RESULTS
There were 1667 responders to the survey, 249 of whom had pre-existing IBS. Of the 1418 responders without pre-existing IBS, 301 (21%) subsequently developed IBS. Most of these individuals had IBS-mixed (54%), followed by IBS-diarrhea (38%), and IBS-constipation (6%). The mean IBS symptom severity score was 218 (indicating moderate severity). Female sex, younger age, bloody stools, abdominal cramps, and hospitalization during acute enteritis were associated with increased risk, whereas fever was protective for the development of PI-IBS. Antibiotic use and exposure patterns were similar between PI-IBS and control groups. Among patients with IBS-mixed or IBS-diarrhea before infection, 78% retained their subtypes after infection. In contrast, only 50% of patients with IBS-constipation retained that subtype after infection, whereas 40% transitioned to IBS-mixed. Of patients with pre-existing IBS, 38% had increased frequency of abdominal pain after Campylobacter infection.
CONCLUSIONS
In a cohort of patients with Campylobacter infection in Minnesota, 21% developed PI-IBS; most cases reported mixed IBS or diarrhea of moderate severity. Demographic and clinical factors during acute enterocolitis are associated with PI-IBS development. Campylobacter infection also can result in a switch of a pre-existing IBS phenotype.
Identifiants
pubmed: 32711045
pii: S1542-3565(20)30995-2
doi: 10.1016/j.cgh.2020.07.033
pmc: PMC8994162
mid: NIHMS1615595
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1855-1863.e1Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK103911
Pays : United States
Organisme : NIDDK NIH HHS
ID : R03 DK120745
Pays : United States
Informations de copyright
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
MMWR Morb Mortal Wkly Rep. 2019 Apr 26;68(16):369-373
pubmed: 31022166
J Neurogastroenterol Motil. 2012 Apr;18(2):200-4
pubmed: 22523730
MMWR Surveill Summ. 2018 Jul 27;67(10):1-11
pubmed: 30048426
BMC Gastroenterol. 2009 Apr 21;9:27
pubmed: 19383162
Nat Rev Dis Primers. 2016 Mar 24;2:16014
pubmed: 27159638
Gastroenterology. 2019 Jan;156(1):46-58.e7
pubmed: 30009817
Gastroenterology. 2007 Sep;133(3):799-807
pubmed: 17678917
Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
pubmed: 9146781
Neurogastroenterol Motil. 2019 Jan;31(1):e13483
pubmed: 30393924
Gastroenterology. 2020 Apr;158(5):1262-1273.e3
pubmed: 31917991
Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4
pubmed: 22426087
Gastroenterology. 2011 Dec;141(6):2098-2108.e5
pubmed: 21856270
Nat Rev Gastroenterol Hepatol. 2011 Oct 25;8(12):669-85
pubmed: 22025030
Gut. 2012 Feb;61(2):214-9
pubmed: 21911849
Am J Gastroenterol. 2012 Jun;107(6):891-9
pubmed: 22525306
Emerg Infect Dis. 2011 Jan;17(1):7-15
pubmed: 21192848
Gastroenterology. 2017 Apr;152(5):1042-1054.e1
pubmed: 28069350
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Gastroenterology. 2006 Aug;131(2):445-50; quiz 660
pubmed: 16890598
Am J Gastroenterol. 2009 Sep;104(9):2267-74
pubmed: 19568228
Gastroenterology. 2003 Dec;125(6):1651-9
pubmed: 14724817
Am J Gastroenterol. 2019 Oct;114(10):1649-1656
pubmed: 31567167